Press release from Companies: RhoVac provides a status update and investigates a potentially accelerated repayment of the convertible loan

Press release from Companies: RhoVac ger statusuppdatering och undersöker förutsättningarna för en accelererad återbetalning av konvertibellånet

Market Notices: Market notice 94/22 – RhoVac AB´s financial instruments are moved to the Observation List

Press release from Companies: RhoVac’s phase IIb study in prostate cancer , BRaVac, failed to meet its primary endpoint

Press release from Companies: RhoVacs fas IIb-studie, BRaVac, lyckades inte nå sin "Primary Endpoint"

Press release from Companies: Pre-clinical findings support the potential use of RhoVac’s drug candidate, onilcamotide, across several cancers

Press release from Companies: Pre-clinical findings support the potential use of RhoVac’s drug candidate, onilcamotide, across several cancers

Press release from Companies: Prekliniska fynd stödjer den potentiella användningen av RhoVacs läkemedels-kandidat, onilcamotide, i flera cancerformer

Press release from Companies: Kommuniké från årsstämma onsdagen den 18 maj i RhoVac AB

Press release from Companies: Kommuniké från årsstämma onsdagen den 18 maj i RhoVac AB

Press release from Companies: RhoVac AB tillkännager databasstängning ("Database Lock") i sin kliniska fas IIb-studie med onilcamotide

Press release from Companies: RhoVac AB tillkännager databasstängning ("Database Lock") i sin kliniska fas IIb-studie med onilcamotide